{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:31:13Z","timestamp":1788957073990,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00774-024-01531-5","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:02:07Z","timestamp":1720443727000},"page":"492-502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-5440","authenticated-orcid":false,"given":"Takaomi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Shimanoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadatsugu","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawatari","family":"Masaaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"1531_CR1","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00198-022-06454-3","volume":"33","author":"PL Xiao","year":"2022","unstructured":"Xiao PL, Cui AY, Hsu CJ, Peng R, Jiang N, Xu XH, Ma YG, Liu D, Lu HD (2022) Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int 33:2137\u20132153","journal-title":"Osteoporos Int"},{"key":"1531_CR2","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jc.2009-0852","volume":"95","author":"MJ Bolland","year":"2010","unstructured":"Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174\u20131181","journal-title":"J Clin Endocrinol Metab"},{"key":"1531_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40265-019-01072-6","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Romosozumab: first global approval. Drugs 79:471\u2013476","journal-title":"Drugs"},{"key":"1531_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105:587\u2013594","journal-title":"J Clin Endocrinol Metab"},{"key":"1531_CR5","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193","journal-title":"J Clin Endocrinol Metab"},{"key":"1531_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215","journal-title":"Bone"},{"key":"1531_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3803\/EnM.2020.848","volume":"36","author":"KH Baek","year":"2021","unstructured":"Baek KH, Chung YS, Koh JM, Kim IJ, Kim KM, Min YK, Park KD, Dinavahi R, Maddox J, Yang W, Kim S, Lee SJ, Cho H, Lim SK (2021) Romosozumab in postmenopausal Korean women with osteoporosis: a randomized, double-blind, placebo-controlled efficacy and safety study. Endocrinol Metab (Seoul) 36:60\u201369","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1531_CR8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"1531_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"1531_CR10","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). (2018) A randomized phase 3 study to evaluate two formulations of romosozumab in postmenopausal women with osteoporosis. Identifier: NCT02016716. Retrieved 9 January, 2024 from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02016716"},{"key":"1531_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00774-022-01332-8","volume":"40","author":"A Miyauchi","year":"2022","unstructured":"Miyauchi A, Hamaya E, Nishi K, Tolman C, Shimauchi J (2022) Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab 40:677\u2013687","journal-title":"J Bone Miner Metab"},{"key":"1531_CR12","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s00198-022-06544-2","volume":"33","author":"B Langdahl","year":"2022","unstructured":"Langdahl B, Hofbauer LC, Ferrari S, Wang Z, Fahrleitner-Pammer A, Gielen E, Lakatos P, Czerwinski E, Gimeno EJ, Timoshanko J, Oates M, Libanati C (2022) Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. Osteoporos Int 33:2527\u20132536","journal-title":"Osteoporos Int"},{"key":"1531_CR13","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37:1437\u20131445","journal-title":"J Bone Miner Res"},{"key":"1531_CR14","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, Yan C, Yue S, Dinavahi RV, Libanati C, Grauer A (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30:2437\u20132448","journal-title":"Osteoporos Int"},{"key":"1531_CR15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397\u20131406","journal-title":"J Bone Miner Res"},{"key":"1531_CR16","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"1531_CR17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1531_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","volume":"33","author":"S Singh","year":"2022","unstructured":"Singh S, Dutta S, Khasbage S, Kumar T, Sachin J, Sharma J, Varthya SB (2022) A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int 33:1\u201312","journal-title":"Osteoporos Int"},{"key":"1531_CR19","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","volume":"39","author":"S Kaveh","year":"2020","unstructured":"Kaveh S, Hosseinifard H, Ghadimi N, Vojdanian M, Aryankhesal A (2020) Efficacy and safety of romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol 39:3261\u20133276","journal-title":"Clin Rheumatol"},{"key":"1531_CR20","doi-asserted-by":"publisher","first-page":"1188969","DOI":"10.3389\/fendo.2023.1188969","volume":"14","author":"M Hu","year":"2023","unstructured":"Hu M, Zhang Y, Guo J, Guo C, Yang X, Ma X, Xu H, Xiang S (2023) Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis. Front Endocrinol (Lausanne) 14:1188969","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1531_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/pds.5594","volume":"32","author":"W Huang","year":"2023","unstructured":"Huang W, Nagao M, Yonemoto N, Guo S, Tanigawa T, Nishizaki Y (2023) Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials (CDM-J). Pharmacoepidemiol Drug Saf 32:671\u2013684","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1531_CR22","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/os.13136","volume":"13","author":"A Tian","year":"2021","unstructured":"Tian A, Jia H, Zhu S, Lu B, Li Y, Ma J, Ma X (2021) Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence. Orthop Surg 13:1941\u20131950","journal-title":"Orthop Surg"},{"key":"1531_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jocd.2021.11.005","volume":"25","author":"F Poutoglidou","year":"2022","unstructured":"Poutoglidou F, Samoladas E, Raikos N, Kouvelas D (2022) Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: a meta-analysis and systematic review. J Clin Densitom 25:401\u2013415","journal-title":"J Clin Densitom"},{"key":"1531_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12891-019-2769-8","volume":"20","author":"YZ Jin","year":"2019","unstructured":"Jin YZ, Lee JH, Xu B, Cho M (2019) Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 20:399","journal-title":"BMC Musculoskelet Disord"},{"key":"1531_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/mab.2019.0049","volume":"39","author":"G Mariscal","year":"2020","unstructured":"Mariscal G, Nu\u00f1ez JH, Bhatia S, Barrios C, Domenech-Fern\u00e1ndez P (2020) Safety of romosozumab in osteoporotic men and postmenopausal women: a meta-analysis and systematic review. Monoclon Antib Immunodiagn Immunother 39:29\u201336","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"1531_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","volume":"21","author":"Y Liu","year":"2018","unstructured":"Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J (2018) Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 21:189\u2013195","journal-title":"Climacteric"},{"key":"1531_CR27","doi-asserted-by":"publisher","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","volume":"130","author":"F Lv","year":"2020","unstructured":"Lv F, Cai X, Yang W, Gao L, Chen L, Wu J, Ji L (2020) Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta-analysis. Bone 130:115121","journal-title":"Bone"},{"key":"1531_CR28","doi-asserted-by":"publisher","first-page":"eaay6570","DOI":"10.1126\/scitranslmed.aay6570","volume":"12","author":"J Bovijn","year":"2020","unstructured":"Bovijn J, Krebs K, Chen CY, Boxall R, Censin JC et al (2020) Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med. 12:eaay6570","journal-title":"Sci Transl Med."},{"key":"1531_CR29","doi-asserted-by":"publisher","first-page":"116610","DOI":"10.1016\/j.bone.2022.116610","volume":"167","author":"AH Seeto","year":"2023","unstructured":"Seeto AH, Tadrous M, Gebre AK, Lewis JR, Fink HA, Ebeling PR, Rodr\u00edguez AJ (2023) Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone 167:116610","journal-title":"Bone"},{"key":"1531_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.afos.2020.02.003","volume":"6","author":"L M\u00f6ckel","year":"2020","unstructured":"M\u00f6ckel L, Bartneck M, M\u00f6ckel C (2020) Risk of falls in postmenopausal women treated with romosozumab: preliminary indices from a meta-analysis of randomized, controlled trials. Osteoporos Sarcopenia 6:20\u201326","journal-title":"Osteoporos Sarcopenia"},{"key":"1531_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, Mohammadi M (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609","journal-title":"J Orthop Surg Res"},{"key":"1531_CR32","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","volume":"35","author":"C Beaudart","year":"2023","unstructured":"Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N, Fuggle N, Bruy\u00e8re O, Rizzoli R, Reginster JY (2023) Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res 35:1789\u20131806","journal-title":"Aging Clin Exp Res"},{"key":"1531_CR33","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"1531_CR34","unstructured":"Ryan R, Hill S, Prictor M, McKenzie J (2013) Cochrane consumers and communication review group study quality guide. Retrieved 9 January, 2024 from http:\/\/cccrg.cochrane.org\/author- resources.pdf"},{"key":"1531_CR35","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722\u2013733","journal-title":"JAMA"},{"key":"1531_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.4157","volume":"36","author":"AH Seeto","year":"2021","unstructured":"Seeto AH, Abrahamsen B, Ebeling PR, Rodr\u00edguez AJ (2021) Cardiovascular safety of denosumab across multiple indications: a systematic review and meta-analysis of randomized trials. J Bone Miner Res 36:24\u201340","journal-title":"J Bone Miner Res"},{"key":"1531_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26:53\u201377","journal-title":"Stat Med"},{"key":"1531_CR38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","volume":"7","author":"M Richardson","year":"2019","unstructured":"Richardson M, Garner P, Donegan S (2019) Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Global Health 7:192\u2013198","journal-title":"Clin Epidemiol Global Health"},{"key":"1531_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775\u2013780","journal-title":"Osteoporos Int"},{"key":"1531_CR40","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721\u2013739","journal-title":"J Bone Miner Res"},{"key":"1531_CR41","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1359\/jbmr.090207","volume":"24","author":"J Ryg","year":"2009","unstructured":"Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977\u20132001. J Bone Miner Res 24:1299\u20131307","journal-title":"J Bone Miner Res"},{"key":"1531_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s00391-020-01784-5","volume":"54","author":"L M\u00f6ckel","year":"2021","unstructured":"M\u00f6ckel L (2021) Risk of falls in patients with low bone mineral density: analysis of placebo arms from clinical trials. Z Gerontol Geriatr 54:576\u2013581","journal-title":"Z Gerontol Geriatr"},{"key":"1531_CR43","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00198-013-2450-2","volume":"25","author":"R Armamento-Villareal","year":"2014","unstructured":"Armamento-Villareal R, Aguirre L, Napoli N, Shah K, Hilton T, Sinacore DR, Qualls C, Villareal DT (2014) Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults. Osteoporos Int 25:551\u2013558","journal-title":"Osteoporos Int"},{"key":"1531_CR44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/a-0979-2581","volume":"29","author":"L M\u00f6ckel","year":"2020","unstructured":"M\u00f6ckel L (2020) Less falls in osteoporosis patients treated with teriparatide: a meta-analysis. Osteologie 29:31\u201338","journal-title":"Osteologie"},{"key":"1531_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/BCO.0000000000000563","volume":"28","author":"T Tsuda","year":"2017","unstructured":"Tsuda T (2017) Epidemiology of fragility fractures and fall prevention in the elderly: a systematic review of the literature. Curr Orthop Pract 28:580\u2013585","journal-title":"Curr Orthop Pract"},{"key":"1531_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jbmr.3860","volume":"35","author":"IR Reid","year":"2020","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD (2020) Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res 35:20\u201327","journal-title":"J Bone Miner Res"},{"key":"1531_CR47","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1080\/14740338.2022.2160445","volume":"21","author":"IR Reid","year":"2022","unstructured":"Reid IR (2022) What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab? Expert Opin Drug Saf 21:1441\u20131443","journal-title":"Expert Opin Drug Saf"},{"key":"1531_CR48","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","volume":"11","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep 11:11801","journal-title":"Sci Rep"},{"key":"1531_CR49","doi-asserted-by":"publisher","first-page":"116480","DOI":"10.1016\/j.bone.2022.116480","volume":"162","author":"T Kobayakawa","year":"2022","unstructured":"Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y (2022) Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: the prospective VICTOR study. Bone 162:116480","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01531-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-024-01531-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01531-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T15:02:26Z","timestamp":1728140546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-024-01531-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1007\/s00774-024-01531-5","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.K., M.H., C.S., T.M., M.M., K.I., and T.S. declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}